An insight to PDAC tumor heterogeneity across pancreatic subregions using computed tomography images

An insight to PDAC tumor heterogeneity across pancreatic subregions using computed tomography images

Pancreatic Ductal Adenocarcinoma (PDAC) is an exceptionally deadly form of pancreatic cancer with an extremely low survival rate. From diagnosis to treatment, PDAC is highly challenging to manage. Studies have demonstrated that PDAC tumors in distinct regions of the pancreas exhibit unique character...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sehrish Javed, Touseef Ahmad Qureshi, Lixia Wang, Linda Azab, Srinivas Gaddam, Stephen J. Pandol, Debiao Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-11-01
Series:	Frontiers in Oncology
Subjects:	pancreatic ductal adenocarcinoma (PDAC) tumor heterogeneity pancreatic subregions radiomics pancreas cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1378691/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Microbiome in pancreatic cancer – What is new in 2024?
by: E. Hohmann, et al.
Published: (2024-10-01)

Most oncological pancreas resections must consider the mesopancreas
by: S. A. Safi, et al.
Published: (2025-02-01)

Does acute pancreatitis herald pancreatic ductal adenocarcinoma? A multicenter electronic health research network study
by: Ritu R. Singh, et al.
Published: (2023-02-01)

Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential against gemcitabine-resistant PDAC
by: Zehui Yao, et al.
Published: (2025-01-01)

Prolonged survival by combination treatment with a standardized herbal extract from Japanese Kampo-medicine (Juzentaihoto) and gemcitabine in an orthotopic transplantation pancreatic cancer model
by: Joanna Napp, et al.
Published: (2024-12-01)

Comparison of multiple machine learning models for predicting prognosis of pancreatic ductal adenocarcinoma based on contrast-enhanced CT radiomics and clinical features
by: Yue Huang, et al.
Published: (2024-11-01)

Development of a Machine‐Learning Model for Diagnosis of Pancreatic Cancer from Serum Samples Analyzed by Thermal Liquid Biopsy
by: Sonia Hermoso‐Durán, et al.
Published: (2025-01-01)

Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
by: Heng‐Chung Kung, et al.
Published: (2023-04-01)

Intra-tumoral administration of CHST15 siRNA remodels tumor microenvironment and augments tumor-infiltrating T cells in pancreatic cancer
by: Juanjuan Ye, et al.
Published: (2024-06-01)

Epithelial–Mesenchymal Transition Suppression by ML210 Enhances Gemcitabine Anti-Tumor Effects on PDAC Cells
by: Keisuke Takemura, et al.
Published: (2025-01-01)

The Potential of TRPA1 as a Therapeutic Target in Cancer—A Study Using Bioinformatic Tools
by: Dana Cucu
Published: (2024-12-01)

Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial
by: Michael Ghadimi, et al.
Published: (2025-02-01)

Stereotactic Radiotherapy Plus Nivolumab in Patients with Locally Advanced Pancreatic Cancer: Results from Phase 1/2 Clinical CA209-9KH Trial
by: Milan Vošmik, et al.
Published: (2024-10-01)

Reprogramming tumor-associated macrophages with lipid nanosystems reduces PDAC tumor burden and liver metastasis
by: Adrián Palencia-Campos, et al.
Published: (2024-12-01)

Single-cell transcriptomics analysis reveals dynamic changes and prognostic signature in tumor microenvironment of PDAC
by: Yongsheng Li, et al.
Published: (2025-02-01)

Adjuvant 5‐fluorouracil and portal vein infusion chemotherapy followed by gemcitabine for pancreatic cancer
by: Minoru Kitago, et al.
Published: (2024-07-01)

Botanical drugs and their natural compounds: a neglected treasury for inhibiting the carcinogenesis of pancreatic ductal adenocarcinoma
by: Yunfei Dai, et al.
Published: (2024-12-01)

Association between preoperative exercise tolerance and unplanned readmission in patients who underwent pancreatectomy for pancreatic ductal adenocarcinoma: a retrospective analysis
by: Makoto Onji, et al.
Published: (2025-01-01)

Peripheral Eosinophil Count May Be the Prognostic Factor for Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Treatment
by: Wojciech Ciesielski, et al.
Published: (2024-11-01)

Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club
by: Katarzyna Winter, et al.
Published: (2019-03-01)

FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival
by: Nathalie B. Rasko, et al.
Published: (2025-01-01)

Perioperative outcomes in an age-adapted analysis of the German StuDoQ|Pancreas registry for PDAC
by: Tengis Tschaidse, et al.
Published: (2025-01-01)

Identification of SMAD4-mutated pancreatic ductal adenocarcinoma using preoperative contrast-enhanced MRI and clinical characteristics
by: Zhina Li, et al.
Published: (2024-12-01)

AHNAK2: a potential diagnostic biomarker for pancreatic cancer related to cellular motility
by: Mohamed Zardab, et al.
Published: (2025-01-01)

Tumor-Colonizing <i>E. coli</i> Expressing Both Collagenase and Hyaluronidase Enhances Therapeutic Efficacy of Gemcitabine in Pancreatic Cancer Models
by: Lara C. Avsharian, et al.
Published: (2024-11-01)

Realising the therapeutic potential of the human microbiota in metastatic pancreatic ductal adenocarcinoma
by: James M. Halle-Smith, et al.
Published: (2023-12-01)

Gene Expression Profiling of Pancreatic Ductal Adenocarcinoma Arising From Intraductal Papillary Mucinous Neoplasms of the Pancreas
by: William A. Ziaziaris, et al.
Published: (2024-12-01)

Epigenetic Landscape of DNA Methylation in Pancreatic Ductal Adenocarcinoma
by: Peiyi Liu, et al.
Published: (2024-11-01)

Diseases of the pancreas (<i>Review of the Seventeenth Russian Gastroenterological Week proceedings, October, 10–12, 2011, Moscow</i>)
by: I. V. Mayev, et al.
Published: (2012-06-01)

Circular RNA expression profiles in extracellular vesicles from the plasma of patients with pancreatic ductal adenocarcinoma
by: Qingqing Li, et al.
Published: (2019-12-01)

Identification and validation of a novel autoantibody biomarker panel for differential diagnosis of pancreatic ductal adenocarcinoma
by: Metoboroghene O. Mowoe, et al.
Published: (2025-01-01)

Chronic pancreatitis: issues remain unresolved
by: V. T. Ivashkin, et al.
Published: (2015-09-01)

Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2
by: Hemant M. Kocher, et al.
Published: (2025-01-01)

Familial Pancreatic Cancer Research: Bridging Gaps in Basic Research and Clinical Application
by: Suyakarn Archasappawat, et al.
Published: (2024-10-01)

Genetically predicted gut bacteria, circulating bacteria-associated metabolites and pancreatic ductal adenocarcinoma: a Mendelian randomisation study
by: Neil Daniel, et al.
Published: (2024-10-01)

Efficacy and safety of neoadjuvant S-1-based chemoradiotherapy in resectable and borderline-resectable pancreatic cancer: a long-term follow-up study
by: Gaku Shimane, et al.
Published: (2024-12-01)

GNG12 regulates PD‐L1 expression by activating NF‐κB signaling in pancreatic ductal adenocarcinoma
by: Juan Li, et al.
Published: (2020-02-01)

CASC8 activates the pentose phosphate pathway to inhibit disulfidptosis in pancreatic ductal adenocarcinoma though the c-Myc-GLUT1 axis
by: Hong-Fei Yao, et al.
Published: (2025-01-01)

Elevated SAMD3 expression in T cells predicts improved survival in pancreatic ductal adenocarcinoma patients
by: Lingyi Fu, et al.
Published: (2025-02-01)

The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration
by: Chiara Cencioni, et al.
Published: (2025-01-01)